Response Oncology Stock Earnings Per Share
Response Oncology fundamentals help investors to digest information that contributes to Response Oncology's financial success or failures. It also enables traders to predict the movement of Response Stock. The fundamental analysis module provides a way to measure Response Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Response Oncology stock.
Response |
Response Oncology Company Earnings Per Share Analysis
Response Oncology's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Response Oncology Earnings Per Share | (4.16) X |
Most of Response Oncology's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Response Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Response Oncology has an Earnings Per Share of -4.158 times. This is much lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The earnings per share for all United States stocks is notably higher than that of the company.
Response Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Response Oncology's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Response Oncology could also be used in its relative valuation, which is a method of valuing Response Oncology by comparing valuation metrics of similar companies.Response Oncology is currently under evaluation in earnings per share category among its peers.
Response Fundamentals
| Return On Equity | -7.24 | |||
| Return On Asset | -0.0153 | |||
| Profit Margin | (0.47) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 16.62 M | |||
| Shares Outstanding | 12.18 M | |||
| Revenue | 118.08 M | |||
| Gross Profit | 28.17 M | |||
| EBITDA | 1.32 M | |||
| Net Income | (51.39 M) | |||
| Cash And Equivalents | 9.01 M | |||
| Cash Per Share | 0.74 X | |||
| Total Debt | 26.45 M | |||
| Current Ratio | 13.35 X | |||
| Book Value Per Share | (1.54) X | |||
| Cash Flow From Operations | 9.1 M | |||
| Earnings Per Share | (4.16) X | |||
| Number Of Employees | 10 | |||
| Beta | -19.24 | |||
| Market Capitalization | 12 | |||
| Total Asset | 28.9 M | |||
| Retained Earnings | (120.16 M) | |||
| Working Capital | 34.72 M | |||
| Current Asset | 37.25 M | |||
| Current Liabilities | 2.54 M | |||
| Z Score | -0.15 | |||
| Net Asset | 28.9 M |
About Response Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Response Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Response Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Response Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |